{"id":"novavax-covid-19-vaccine","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site pain"},{"rate":"35-45","effect":"Fatigue"},{"rate":"30-40","effect":"Myalgia"},{"rate":"25-35","effect":"Headache"},{"rate":"10-15","effect":"Fever"},{"rate":"5-10","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL6068383","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains recombinant SARS-CoV-2 spike protein produced in insect cells, assembled into nanoparticles, and formulated with Matrix-M adjuvant to enhance immunogenicity. This protein-based approach differs from mRNA vaccines by delivering the antigen directly rather than instructing cells to produce it, triggering both humoral and cellular immune responses to prevent COVID-19 infection and severe disease.","oneSentence":"Novavax COVID-19 Vaccine uses recombinant spike protein nanoparticles with a saponin-based adjuvant to stimulate immune responses against SARS-CoV-2.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:22.278Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention in adults 18 years and older"},{"name":"COVID-19 prevention in adolescents 12-17 years (in some jurisdictions)"}]},"trialDetails":[{"nctId":"NCT07051031","phase":"PHASE4","title":"COVID-19 Reactogenicity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Marcel Curlin","startDate":"2025-10-01","conditions":"COVID-19","enrollment":1000},{"nctId":"NCT07408297","phase":"PHASE2","title":"Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda","status":"COMPLETED","sponsor":"Victoria Biomedical Research Institute","startDate":"2022-05-18","conditions":"COVID -19, SARS CoV 2 Infection","enrollment":1919},{"nctId":"NCT06065176","phase":"PHASE4","title":"The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection","status":"COMPLETED","sponsor":"Sarang K. Yoon, DO, MOH","startDate":"2023-11-22","conditions":"COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection","enrollment":1188},{"nctId":"NCT05658523","phase":"PHASE3","title":"COVID-19 Booster Study in Healthy Adults in Australia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2023-02-28","conditions":"COVID-19","enrollment":496},{"nctId":"NCT07287137","phase":"PHASE4","title":"Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study","status":"RECRUITING","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2025-11-12","conditions":"COVID -19, COVID - 19, COVID 19","enrollment":54},{"nctId":"NCT06027229","phase":"PHASE2","title":"Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2023-11-20","conditions":"Immunosuppression, COVID-19","enrollment":21},{"nctId":"NCT06291857","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novavax","startDate":"2024-12-09","conditions":"COVID-19","enrollment":9320},{"nctId":"NCT05875701","phase":"PHASE3","title":"Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines","status":"COMPLETED","sponsor":"Novavax","startDate":"2023-03-28","conditions":"COVID-19","enrollment":147},{"nctId":"NCT03305341","phase":"EARLY_PHASE1","title":"Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix","status":"ACTIVE_NOT_RECRUITING","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","startDate":"2025-05-18","conditions":"Covid19","enrollment":20},{"nctId":"NCT06633835","phase":"PHASE4","title":"Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novavax","startDate":"2024-09-20","conditions":"COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection","enrollment":660},{"nctId":"NCT05249816","phase":"PHASE3","title":"Phase 3 Boosting Study for the SARS-CoV-2 rS Vaccine","status":"COMPLETED","sponsor":"Cogna Technology Solutions LLC","startDate":"2022-03-18","conditions":"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","enrollment":1000},{"nctId":"NCT05236491","phase":"PHASE2, PHASE3","title":"COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases","status":"UNKNOWN","sponsor":"Paul R Fortin","startDate":"2022-03-09","conditions":"Rheumatoid Arthritis, Autoimmune Rheumatologic Disease, Systemic Lupus Erythematosus","enrollment":287},{"nctId":"NCT04834869","phase":"","title":"COVID-19 Vaccines Safety Tracking (CoVaST)","status":"RECRUITING","sponsor":"Masaryk University","startDate":"2021-04-01","conditions":"Adverse Reaction to Vaccine, COVID19 Vaccine","enrollment":30000}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"BLOOD PRESSURE DECREASED"},{"count":3,"reaction":"COUGH"},{"count":3,"reaction":"COVID-19"},{"count":3,"reaction":"DYSPNOEA"},{"count":3,"reaction":"NAUSEA"},{"count":3,"reaction":"PERIPHERAL SWELLING"},{"count":3,"reaction":"PRODUCT DOSE OMISSION ISSUE"},{"count":3,"reaction":"WEIGHT DECREASED"},{"count":2,"reaction":"ALOPECIA"},{"count":2,"reaction":"CONTUSION"}],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Novavax SARS-CoV-2 rS vaccine"],"phase":"phase_3","status":"active","brandName":"Novavax COVID-19 Vaccine","genericName":"Novavax COVID-19 Vaccine","companyName":"Novavax","companyId":"novavax","modality":"Biologic","firstApprovalDate":"","aiSummary":"Novavax COVID-19 Vaccine uses recombinant spike protein nanoparticles with a saponin-based adjuvant to stimulate immune responses against SARS-CoV-2. Used for COVID-19 prevention in adults 18 years and older, COVID-19 prevention in adolescents 12-17 years (in some jurisdictions).","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}